Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple risk calculator help catch prostate cancer earlier in nigerian men?

NCT ID NCT07733440

Knowledge-focused Sponsor: Ahmadu Bello University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This pilot trial tests whether a risk calculator designed for Nigerian men can help primary care providers better identify those with clinically significant prostate cancer. Researchers will train healthcare workers at community hospitals and then support them in using the tool for at least six months. The main goal is to see if the calculator is feasible and acceptable in everyday practice, not yet to measure its impact on cancer outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Training and supported risk assessment using a prostate cancer risk calculator
What this could lead to
If successful, this approach could improve early detection of prostate cancer in Nigerian men, potentially saving lives through earlier treatment.
What could go wrong
This is a small pilot study focused on feasibility, not on directly measuring cancer outcomes. The risk calculator may not work as well in real-world settings or may not be adopted by providers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 89 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2029

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Training - Eligible primary care providers (for the training surveys) will be healthcare practitioners at community-level hospitals. 2. Supported Risk Assessment (i) Eligible key informants will be eligible primary care providers who were trained and implemented the supported risk assessment and the targeted population of patient participants who received the supported risk assessment. (ii) Eligible patient participants (for the collection of observation data) will be the target population of adult males 40 - 79 years accessing provider services. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AFRICA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AFRICA Algorithms Biomarker Clinical decision support systems Community health services Evidence-based practice Global health Implementation research MODELS Nigeria Predictive value of tests Primary health care Prostate cancer Prostate specific antigen Risk assessment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ahmadu Bello University Teaching Hospital

    Zaria, Kaduna State, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.